Cybin (CYBN) received a ‘Buy’ rating from two major analysts, Roth Capital and Canaccord Genuity, following the announcement that it will acquire Entheon’s DMT study. Shares are currently priced at $0.60, but the firms predict price targets of $10 and $7.50, respectively.